Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 18k
28 September 2018
E-004938-18
Question for written answer E-004938-18
to the Commission
Rule 130
Theodoros Zagorakis (PPE)

 Subject:  Early access to treatment for patients with lung cancer

In 2017, Lung Cancer Europe presented the European Parliament with a report on the inequalities existing in the EU between lung cancer patients in terms of access to diagnosis, innovative medicines and healthcare services. It is revealing that between 2010 and 2014, while 49 new anticancer drugs were released, only six countries had access to at least half of them.

Characteristically, there are country-by-country differences both in the time of approval of new drugs and in the timely diagnosis of patients and reimbursement, in particular in connection with innovative treatments.

In view of the above, will the Commission say:

Is it aware of this particular report? Has it taken any measures to reduce patient waiting times and improve healthcare for such patients in the EU?

How does it support the scientific community in prevention, research and innovation in fighting lung cancer?

Original language of question: EL 
Last updated: 10 October 2018Legal notice